Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy DermTech stock

Own DermTech stock in just a few minutes.

DermTech, Inc is a diagnostics & research business based in the US. DermTech shares (DMTK) are listed on the NASDAQ and all prices are listed in US Dollars. DermTech employs 114 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in DermTech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DMTK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

DermTech share price

Use our graph to track the performance of DMTK stocks over time.

DermTech shares at a glance

Information last updated 2021-04-29.
52-week range$9.64 - $84.49
50-day moving average $48.40
200-day moving average $35.45
Wall St. target price$64.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.08

Buy DermTech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy DermTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DermTech financials

Revenue TTM $5.9 million
Gross profit TTM $-96,000
Return on assets TTM -48.7%
Return on equity TTM -92.79%
Profit margin 0%
Book value $1.58
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting DermTech shares

There are currently 4.8 million DermTech shares held short by investors – that's known as DermTech's "short interest". This figure is 2.7% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting DermTech shares can be evaluated.

DermTech's "short interest ratio" (SIR)

DermTech's "short interest ratio" (SIR) is the quantity of DermTech shares currently shorted divided by the average quantity of DermTech shares traded daily (recently around 1.3 million). DermTech's SIR currently stands at 3.55. In other words for every 100,000 DermTech shares traded daily on the market, roughly 3550 shares are currently held short.

However DermTech's short interest can also be evaluated against the total number of DermTech shares, or, against the total number of tradable DermTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DermTech's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 DermTech shares in existence, roughly 170 shares are currently held short) or 0.2025% of the tradable shares (for every 100,000 tradable DermTech shares, roughly 203 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DermTech.

Find out more about how you can short DermTech stock.

DermTech share dividends

We're not expecting DermTech to pay a dividend over the next 12 months.

Have DermTech's shares ever split?

DermTech's shares were split on a 1:2 basis on 29 August 2019. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DermTech shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for DermTech shares which in turn could have impacted DermTech's share price.

DermTech overview

DermTech, Inc. , a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site